Europe’s drug patent system: how long protection lasts—and where it quietly breaks down
If you’re building a pipeline, underwriting risk, or pricing a launch strategy, the question isn’t “Do patents exist?” It’s “For how long, in practice, will exclusi…

Drug discovery timelines are getting longer. GPT + Rosalind could be the lever that changes the math.
If you’ve worked anywhere near R&D, you’ve felt it: the clock keeps ticking, budgets tighten, and the “time-to-answer” keeps stretching. In pharma…

The “Patent Expiration Cliff” Isn’t a Cliff—It’s a Calendar Problem. Here’s How Commercial Teams Can Stop Getting Blindsided.
If you’ve ever watched a branded product’s revenue curve bend sharply overnight, you already know the story: the patent expira…

Authorized Generics: The Innovator’s Playbook for Diluting First-Filer Profits
The first-filer advantage in generics is supposed to be a clean story: win the patent case, launch early, capture a premium window of exclusivity, and monetize the payoff.
B…

Read the clock right: Mapping regulatory exclusivities for true generic entry timing
Most people think “generic entry” is a single date on a calendar. In reality, it’s a moving target—set by a web of regulatory exclusivities, patent thickets, and timin…

Unlocking the Hidden Clock: How Precise Mapping of Regulatory Exclusivities Can Accelerate Generic Drug Entry
In the complex world of pharmaceutical innovation and market competition, timing is everything. Yet, for many stakeholders—manufacturers, inve…

The real “winner” in generic drug battles isn’t the company with the best science—it’s the one that understands timing, leverage, and the rules of the patent war.
When a brand-name drug’s exclusivity is nearing its end, the market doesn’t just wait for…

Consumers Pay a “Trust Premium” for Branded Generics—And That’s a Signal Investors Shouldn’t Ignore
Walk into any pharmacy and you’ll see it: two products that look nearly identical on the shelf, yet one carries a higher price tag. The difference isn’t…

AI is already “reading” your drug—before your competitors do. Here’s what that means.
In pharma, we’ve spent years perfecting the art of being first: first to file, first to prove, first to win formulary access. But the competitive edge is shifting fro…

Pharma teams are drowning in data—and still making decisions with blind spots.
That’s the uncomfortable truth behind the “intelligence gap” most organizations leave open when they’re trying to read the patent landscape and beat the competition. The res…